Understanding Teglicar: Synthesis, Stability, and Research Applications
The advancement of scientific research often hinges on the availability of high-quality, well-characterized chemical compounds. Teglicar (CAS 250694-07-6), a significant inhibitor of carnitine palmitoyltransferase 1A (L-CPT1), is one such compound that has garnered attention for its roles in metabolic research and oncology. For procurement managers and research scientists, understanding its synthesis, stability, and how to best source it is crucial.
Teglicar's synthesis typically involves a straightforward urea formation reaction. A common method employs the reaction between (R)-aminocarnitine and tetradecylisocyanate, often facilitated by a phase transfer catalyst. This reaction is designed to yield the target compound with high purity. However, a key challenge in working with compounds like Teglicar has historically been their stability, particularly their tendency to be hygroscopic and exist in amorphous forms.
Significant advancements have been made in developing stable crystalline forms of Teglicar, notably Crystalline Form I. This form exhibits superior stability and reduced hygroscopicity compared to amorphous preparations. The careful control of crystallization processes, often involving specific solvents and controlled temperature conditions, is essential for obtaining this highly pure and stable material. For research applications, the stability of the compound directly impacts the reliability and reproducibility of experimental results.
When considering the purchase of Teglicar, it is vital to partner with a reputable manufacturer and supplier. We, as a leading chemical supplier based in China, specialize in providing research-grade chemicals like Teglicar (CAS 250694-07-6). Our stringent quality control ensures that you receive compounds with guaranteed purity and stability. Understanding the needs of our B2B clientele, we offer competitive pricing and reliable supply chains, making it easier for research institutions and pharmaceutical companies to buy Teglicar for their ongoing projects. Trust us to be your supplier for critical research reagents.
Perspectives & Insights
Future Origin 2025
“Teglicar's synthesis typically involves a straightforward urea formation reaction.”
Core Analyst 01
“A common method employs the reaction between (R)-aminocarnitine and tetradecylisocyanate, often facilitated by a phase transfer catalyst.”
Silicon Seeker One
“However, a key challenge in working with compounds like Teglicar has historically been their stability, particularly their tendency to be hygroscopic and exist in amorphous forms.”